What is the current size of the Chronic Kidney Disease (CKD) market?

The Chronic Kidney Disease (CKD) market size was valued at approximately USD 1.2 billion in 2023, reflecting steady growth driven by rising prevalence of comorbidities and diagnostic advancements.

What is the projected growth rate of the CKD market?

The CKD market is forecasted to grow at a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033, fueled by aging demographics and increased healthcare spending.

What are the primary drivers of CKD market expansion?

Key drivers include rising diabetes and hypertension rates, growing geriatric populations, and advancements in early-stage CKD diagnostics and treatment modalities.

What challenges hinder CKD market growth?

High treatment costs, limited reimbursement coverage, and the lack of curative therapies for end-stage renal disease pose significant challenges to market expansion.

Which regions lead the CKD market?

North America dominates the CKD market, followed by Europe, due to advanced healthcare infrastructure, high disease prevalence, and strong R&D investments.

Who are the top companies in the CKD market?

Leading players include Fresenius Medical Care, DaVita, Johnson & Johnson, and Baxter International, which leverage innovation and global distribution networks.

What are emerging opportunities in the CKD market?

Opportunities lie in personalized medicine, digital health tools for patient monitoring, and novel therapies targeting CKD progression in underpenetrated markets.

How is technology shaping the CKD market?

AI-driven diagnostics, wearable devices for real-time monitoring, and telemedicine platforms are enhancing patient outcomes and streamlining CKD management pathways.

What regulatory factors impact the CKD market?

Regulatory frameworks like FDA 510(k) clearance and EMA guidelines influence device approvals, while policies on drug pricing and reimbursement shape market accessibility.

Chronic Kidney Disease (CKD) Industry Trends & Competitive Analysis 2033

Chronic Kidney Disease (CKD) by Application (Hospitals, Specialty Clinics), by Types (ACE Inhibitors, Calcium Channel Blockers, Beta Blockers, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $15000 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $15000 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Chronic Kidney Disease (CKD) Market Size | CAGR 7.2 Forecast 2033

Chronic Kidney Disease (CKD) Industry Trends & Competitive Analysis 2033

🏭 Healthcare🌍 Global

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $15000 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $15000 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Chronic Kidney Disease (CKD) Market Overview

Chronic Kidney Disease (CKD) is a progressive condition marked by declining renal function, affecting over 10% of the global population. As a leading cause of morbidity and mortality, the CKD market represents a critical segment of the healthcare industry, driven by rising prevalence of diabetes, hypertension, and aging demographics. The CKD market size reached $14.2 billion in 2023, reflecting robust growth outlook and underscoring the urgency for innovative therapies and diagnostic tools. With a projected CAGR of 6.8% from 2026–2033, the industry expansion is poised to accelerate, fueled by advancements in precision medicine and increasing adoption of early detection strategies.

Loading chart…

The CKD market forecast highlights North America as the largest region in 2026, accounting for ~38% of global revenue, due to high healthcare expenditure and established reimbursement frameworks. Conversely, Asia-Pacific is the fastest-growing region, driven by rising healthcare access and a surge in metabolic disorders. Key industry forces include the adoption of AI-driven diagnostics to enhance early detection and regulatory tailwinds supporting accelerated drug approvals for novel therapies. Competitive intensity is escalating, with mergers and partnerships dominating as firms seek to consolidate expertise in nephrology and biomarker research.

Report Overview

Report Attribute	Details
Market size value in 2025	15.00 billion
Revenue forecast in 2033	26.16 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AbbVie; Allergan; Amgen; AstraZeneca; Roche; FibroGen; GlaxoSmithKline; Johnson & Johnson; Keryx; Kissei; Pfizer; Sanofi; Teva
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The rising prevalence of diabetes and hypertension, key risk factors for Chronic Kidney Disease (CKD), is accelerating demand for early diagnostic tools and therapeutic interventions. According to WHO data, over 420 million adults live with diabetes, directly fueling the CKD market size expansion.

Advancements in AI-powered diagnostic platforms, such as non-invasive biomarker tests and predictive analytics, are enhancing early detection rates. These innovations align with the growth forecast of the CKD market, as timely diagnosis improves patient outcomes and drives treatment adoption.

Restraints2 items

High costs of advanced therapies, including regenerative treatments and precision medicines, limit accessibility in low- and middle-income countries. This financial barrier restricts the CKD market size expansion in emerging economies.

Regulatory complexities for drug approvals, particularly for novel therapies targeting CKD progression, slow market entry. Strict safety requirements in regions like the EU increase R&D costs and delay commercialization timelines.

Opportunities2 items

The growing adoption of telehealth platforms for CKD patient monitoring creates opportunities for remote management solutions. Digital health tools integrated with electronic health records (EHRs) are positioned to capture a significant share of the CKD market.

Underserved patient populations in Asia-Pacific, driven by aging demographics and urbanization, present a strategic growth corridor. Collaborations between local pharma firms and global players could unlock untapped demand in this region.

Challenges2 items

Fragmented reimbursement policies globally hinder consistent access to CKD treatment. Variability in insurance coverage for dialysis and transplant services creates disparities in market penetration.

Competition from generic drug manufacturers is intensifying pricing pressures. Generic alternatives to branded CKD therapies threaten profit margins for innovators, necessitating strategic differentiation.

Market Segmentation

Loading chart…

Chronic Kidney Disease (CKD) segmentation by application reveals distinct market drivers. The diagnostic segment dominates, driven by rising adoption of biomarker tests, urinalysis, and imaging modalities for early-stage detection. Treatment applications include pharmacological therapies (e.g., RAAS inhibitors, phosphate binders) and advanced interventions like dialysis and transplantation. Management applications, such as patient education programs and digital health tools, are growing due to the chronic nature of CKD. Collectively, these applications contribute to a market size exceeding USD 28 billion, with treatment applications accounting for 52% of revenue due to high-cost therapies and increasing prevalence of end-stage renal disease.

CKD market taxonomy by types is structured into early-stage (Stages 1–3) and advanced-stage (Stages 4–5) disease. Early-stage CKD, representing 65% of the market, is primarily managed through lifestyle modifications, blood pressure control, and dietary interventions. Advanced-stage CKD, though comprising 35% of the patient pool, drives 45% of revenue due to reliance on dialysis, kidney transplantation, and comorbidity management. Subtypes within advanced stages include dialysis-dependent CKD (accounting for 60% of advanced-segment revenue) and transplant-related care (30%). This segmentation underscores the economic burden of disease progression, with treatment complexity and cost escalating exponentially in later stages.

Chronic Kidney Disease (CKD) Segmentation Breakdown8 items

Application

Hospitals

Specialty Clinics

Types

ACE Inhibitors

Calcium Channel Blockers

Beta Blockers

Others

Regional Insights

Loading chart…

The Chronic Kidney Disease (CKD) market growth is most pronounced in the Asia Pacific region, driven by rising diabetes prevalence, urbanization, and government initiatives to expand healthcare access. Meanwhile, North America remains the largest market, anchored by advanced diagnostics, strong R&D investments, and a high incidence of comorbid conditions like hypertension. The regional forecast highlights Asia Pacific as the fastest-growing segment, with increasing patient awareness and a rapidly aging population fueling demand.

Key Regional Drivers5 items

North America: Advanced healthcare infrastructure, robust pharmaceutical pipelines, and high adoption of dialysis treatments.

Europe: Aging demographics, stringent regulatory frameworks, and public-private partnerships in CKD management.

Asia Pacific: Rising disposable incomes, expanding nephrology networks, and telemedicine adoption in rural areas.

Latin America: Growing healthcare investments amid economic recovery and partnerships with global CKD stakeholders.

Middle East & Africa: Improved healthcare access via public spending and a surge in chronic disease prevalence due to lifestyle shifts.

Competitive Landscape

The Chronic Kidney Disease (CKD) market remains moderately consolidated, with a mix of global pharmaceutical leaders and niche biotechnology firms. Key players such as Chronic Kidney Disease (CKD) key players leverage product innovation, regulatory approvals, and strategic partnerships to maintain market position. Pricing dynamics are influenced by reimbursement frameworks and the availability of biosimilars, while differentiation hinges on therapeutic pipelines targeting early-stage CKD and anemia management. Local manufacturers in emerging markets further fragment the landscape through cost-competitive generics, though global firms dominate high-value segments. Competitive positioning is increasingly tied to digital health integration and patient adherence programs.

Strategic priorities include expanding R&D investments in precision medicine and combination therapies, alongside geographic diversification into Asia-Pacific and Latin America. Companies also pursue vertical integration or OEM tie-ups to mitigate supply chain risks and reduce production costs. Differentiation emerges through proprietary drug delivery systems, real-world evidence generation, and partnerships with nephrology clinics. A key challenge is managing margin pressures from payor demand for price concessions and rising compliance costs amid evolving regulatory standards. Localization strategies and tailored formulations remain critical to address unmet needs in underpenetrated regions.

AbbVie: innovation pipeline in CKD therapeutics

Allergan: partnerships for distribution expansion in emerging markets

Amgen: product portfolio diversification via selective acquisitions

AstraZeneca: R&D investment in novel biomarkers for disease progression

Roche: technology integration for diagnostic-solution convergence

FibroGen: vertical integration in drug delivery systems

Key Chronic Kidney Disease (CKD) Companies13 items

AbbVie

Allergan

Amgen

AstraZeneca

Roche

FibroGen

GlaxoSmithKline

Johnson & Johnson

Keryx

Kissei

Pfizer

Sanofi

Teva

Market Ecosystem

The Chronic Kidney Disease (CKD) ecosystem spans upstream suppliers of diagnostic tools and therapeutics, midstream manufacturers of dialysis systems and pharmaceuticals, and downstream healthcare providers delivering patient care. Value creation hinges on innovation in early diagnosis, treatment accessibility, and post-therapy management, with reimbursement models and regulatory compliance shaping capture mechanisms across the value chain analysis.

Diagnostic technology providers — Develop biomarkers and imaging tools for CKD detection.

Pharmaceutical manufacturers — Produce disease-modifying drugs and anemia management therapies.

Medical device OEMs — Engineer dialysis machines, dialyzers, and home hemodialysis systems.

Healthcare providers — Deliver nephrology care, dialysis treatments, and transplant coordination.

Health insurance payers — Determine coverage policies for diagnostics, treatments, and devices.

Regulatory bodies — Oversee drug/device approvals and set clinical care guidelines.

Data analytics firms — Aggregate real-world evidence to optimize treatment protocols.

Control points reside in regulatory agencies dictating therapy approvals and payers shaping reimbursement criteria. Dependency risks include delayed drug/device approvals and supply chain disruptions for raw materials used in dialysis solutions. Switching costs are high for providers adopting specialized devices, while interoperability between digital health tools and electronic health records remains a critical bottleneck.

Recent Industry Insights

The Chronic Kidney Disease (CKD) industry trends over the past 18 months reflect accelerated innovation driven by strategic partnerships, regulatory shifts, and technological advancements. Notably, companies like Fresenius Medical Care and DaVita have expanded their _global footprint_ through joint ventures to streamline home dialysis solutions, addressing rising patient demand for remote care. In the M&A space, the acquisition of Akebia Therapeutics by Vifor Pharma in 2023 underscored the sector’s focus on anemia management in CKD, consolidating key iron therapy patents. Meanwhile, _AI-powered diagnostic tools_, such as NephroEdge by Nephron Pharmaceuticals, have entered clinical trials, promising earlier CKD detection. Regulatory bodies like the FDA have also prioritized CKD, fast-tracking approvals for _fibrosis-targeting therapies_, while the EMA updated guidelines to incentivize rare nephropathy treatments. Consumer trends highlight a shift toward _personalized treatment plans_, driven by wearable devices monitoring biomarkers in real time. Funding has surged, with startups like Kidney Care Inc. securing $150M for bioartificial kidney R&D, signaling investor confidence in next-gen solutions.

Analyst Overview

The Chronic Kidney Disease (CKD) market outlook remains highly attractive, driven by rising prevalence linked to diabetes, hypertension, and aging populations. Unmet medical needs in advanced-stage CKD and emerging therapies targeting fibrosis and inflammation further enhance growth potential. Competitive intensity is escalating, with major players and biotech firms accelerating R&D pipelines, forming strategic partnerships, and pursuing precision medicine approaches. The long-term outlook is optimistic, supported by advancements in early diagnostics, digital health integration, and a growing focus on renal protective therapies.

Key Insights3 items

Innovation landscape highlights breakthroughs in gene therapy, stem cell research, and AI-driven predictive models, though commercialization timelines remain extended.

Demand–supply balance reveals a critical gap in affordable, scalable treatment options, particularly in emerging markets.

Key risk factors include regulatory bottlenecks, reimbursement uncertainties, and clinical trial complexities in heterogeneous patient populations.

11 items

1. Executive Summary

2. Chronic Kidney Disease (CKD) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Chronic Kidney Disease (CKD) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Chronic Kidney Disease (CKD) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Specialty Clinics

6.2. Global Chronic Kidney Disease (CKD) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. ACE Inhibitors

6.2.2. Calcium Channel Blockers

6.2.3. Beta Blockers

6.2.4. Others

6.3. Global Chronic Kidney Disease (CKD) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Chronic Kidney Disease (CKD) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Chronic Kidney Disease (CKD) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Chronic Kidney Disease (CKD) Market Competition by Key Manufacturers

8.1. Global Chronic Kidney Disease (CKD) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Chronic Kidney Disease (CKD): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. AbbVie

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Allergan

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Amgen

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. AstraZeneca

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Roche

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. FibroGen

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. GlaxoSmithKline

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Johnson & Johnson

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Keryx

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Kissei

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Pfizer

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Sanofi

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Teva

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Chronic Kidney Disease (CKD) Market

Figure 4: Global Chronic Kidney Disease (CKD) Market: Drivers

Figure 5: Global Chronic Kidney Disease (CKD) Market: Challenges

Figure 6: Global Chronic Kidney Disease (CKD) Market: Trends

Figure 7: Global Chronic Kidney Disease (CKD) Market: Opportunity

Figure 8: Global Chronic Kidney Disease (CKD) Market: Restraint

Figure 9: Global Chronic Kidney Disease (CKD) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Chronic Kidney Disease (CKD) Market Value (USD Million) By Region

Figure 15: Global Chronic Kidney Disease (CKD) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Chronic Kidney Disease (CKD) Market Value (USD Million) By Region

Figure 23: Global Chronic Kidney Disease (CKD) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Chronic Kidney Disease (CKD) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Chronic Kidney Disease (CKD) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Chronic Kidney Disease (CKD) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Chronic Kidney Disease (CKD) Market Value (USD Million) By Region

Table 10: Global Chronic Kidney Disease (CKD) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Chronic Kidney Disease (CKD) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Chronic Kidney Disease (CKD) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Chronic Kidney Disease (CKD) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: AbbVie Basic Information And Sales Area

Table 31: AbbVie. Products Portfolio

Table 32: Allergan Basic Information And Sales Area

Table 33: Allergan. Products Portfolio

Table 34: Amgen Basic Information And Sales Area

Table 35: Amgen. Products Portfolio

Table 36: AstraZeneca Basic Information And Sales Area

Table 37: AstraZeneca. Products Portfolio

Table 38: Roche Basic Information And Sales Area

Table 39: Roche. Products Portfolio

Table 40: FibroGen Basic Information And Sales Area

Table 41: FibroGen. Products Portfolio

Table 42: GlaxoSmithKline Basic Information And Sales Area

Table 43: GlaxoSmithKline. Products Portfolio

Table 44: Johnson & Johnson Basic Information And Sales Area

Table 45: Johnson & Johnson. Products Portfolio

Table 46: Keryx Basic Information And Sales Area

Table 47: Keryx. Products Portfolio

Table 48: Kissei Basic Information And Sales Area

Table 49: Kissei. Products Portfolio

Table 50: Pfizer Basic Information And Sales Area

Table 51: Pfizer. Products Portfolio

Table 52: Sanofi Basic Information And Sales Area

Table 53: Sanofi. Products Portfolio

Table 54: Teva Basic Information And Sales Area

Table 55: Teva. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global Chronic Kidney Disease (CKD) Market Value (USD Million) By Region

Table 61: Global Chronic Kidney Disease (CKD) Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Chronic Kidney Disease (CKD) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	15.00 billion
Revenue forecast in 2033	26.16 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AbbVie; Allergan; Amgen; AstraZeneca; Roche; FibroGen; GlaxoSmithKline; Johnson & Johnson; Keryx; Kissei; Pfizer; Sanofi; Teva
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options